Gloria A Salazar1, Shervin Assassi2, Fredrick Wigley3, Laura Hummers3, John Varga4, Monique Hinchcliff4, Dinesh Khanna5, Elena Schiopu5, Kristine Phillips5, Daniel E Furst6, Virginia Steen7, Murray Baron8, Marie Hudson8, Suzanne S Taillefer8, Janet Pope9, Niall Jones10, Peter Docherty11, Nader A Khalidi12, David Robinson13, Robert W Simms14, Richard M Silver15, Tracy M Frech16, Barri J Fessler17, Jerry A Molitor18, Marvin J Fritzler19, Barbara M Segal18, Firas Al-Kassab20, Marilyn Perry2, Jeremy Yang2, Sara Zamanian21, John D Reveille2, Frank C Arnett2, Claudia Pedroza2, Maureen D Mayes2. 1. Division of Rheumatology, University of Texas Medical School at Houston, 6431 Fannin St. MSB 5.270, Houston, TX 77030. Electronic address: gloria.salazarcintora@uth.tmc.edu. 2. Division of Rheumatology, University of Texas Medical School at Houston, 6431 Fannin St. MSB 5.270, Houston, TX 77030. 3. Asthma and Allergy Center, Johns Hopkins University, Baltimore, MD. 4. Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. 5. Division of Rheumatology, University of Michigan, Ann Arbor, MI. 6. Division of Rheumatology, University of California Los Angeles, Los Angeles, CA. 7. Division of Rheumatology, Georgetown University Medical Center, Washington, DC. 8. Division of Rheumatology, McGill University, Jewish General Hospital, Montreal, Québec, Canada. 9. Division of Rheumatology, University of Western Ontario, London, Ontario, Canada. 10. Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada. 11. The Moncton Hospital, South East Regional Health Authority, Moncton, New Brunswick, Canada. 12. Division of Rheumatology, McMaster University, Hamilton, Ontario, Canada. 13. Arthritis Center, University of Manitoba, Winnipeg, Manitoba, Canada. 14. Arthritis Center/Rheumatology, Boston University School of Medicine, Boston, MA. 15. Division of Rheumatology, Medical University of South Carolina, Charleston, SC. 16. Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT. 17. Division of Rheumatology, University of Alabama Birmingham, Birmingham, AL. 18. Division of Rheumatic and Autoimmune Diseases, University of Minnesota, Minneapolis, MN. 19. Department of Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada. 20. Division of Rheumatology, University of Massachusetts Medical School, Worcester, MA. 21. Department of Internal Medicin, Case Western Reserve University, Cleveland, OH.
Abstract
OBJECTIVE: To examine the demographic and clinical characteristics of systemic sclerosis (SSc) patients without antinuclear antibodies (ANA) compared to ANA-positive patients. METHODS: SSc patients enrolled in the Scleroderma Family Registry and DNA Repository were included. Relevant demographic and clinical data were entered by participating sites or obtained by chart review. ANA and SSc-related antibodies were determined in all investigated patients using commercially available kits at our laboratories. RESULTS: This study included 3249 patients, of whom 208 (6.4%) were ANA negative. The proportion of male patients was higher in the ANA-negative group (OR = 1.65; p = 0.008). ANA-negative patients experienced less vasculopathic manifestations of SSc. The percent predicted diffusing capacity of carbon monoxide (DLCO) was higher in ANA-negative patients (p = 0.03). Pulmonary arterial hypertension (PAH) per right heart catheterization was less common in the ANA-negative group (OR = 0.28; p = 0.03). Furthermore, patients with negative ANA had a lower prevalence of telangiectasias and digital ulcers/pits (OR = 0.59, p = 0.03 and OR = 0.38, p = 0.01, respectively). Although diffuse cutaneous involvement was more common, the modified Rodnan Skin Score (mRSS) was lower in the ANA-negative group (2.4 points lower, p = 0.05). Furthermore, they experienced more malabsorption (p = 0.05). There was no difference in the frequency of pulmonary fibrosis or scleroderma renal crisis. All-cause mortality was not different between the 2 groups (p = 0.28). CONCLUSIONS: In conclusion, the results of this study suggest that SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy (less PAH, digital ulcers, and fewer telangiectasias), a greater proportion of males, and possibly, more frequent lower gastrointestinal involvement.
OBJECTIVE: To examine the demographic and clinical characteristics of systemic sclerosis (SSc) patients without antinuclear antibodies (ANA) compared to ANA-positive patients. METHODS: SSc patients enrolled in the Scleroderma Family Registry and DNA Repository were included. Relevant demographic and clinical data were entered by participating sites or obtained by chart review. ANA and SSc-related antibodies were determined in all investigated patients using commercially available kits at our laboratories. RESULTS: This study included 3249 patients, of whom 208 (6.4%) were ANA negative. The proportion of male patients was higher in the ANA-negative group (OR = 1.65; p = 0.008). ANA-negative patients experienced less vasculopathic manifestations of SSc. The percent predicted diffusing capacity of carbon monoxide (DLCO) was higher in ANA-negative patients (p = 0.03). Pulmonary arterial hypertension (PAH) per right heart catheterization was less common in the ANA-negative group (OR = 0.28; p = 0.03). Furthermore, patients with negative ANA had a lower prevalence of telangiectasias and digital ulcers/pits (OR = 0.59, p = 0.03 and OR = 0.38, p = 0.01, respectively). Although diffuse cutaneous involvement was more common, the modified Rodnan Skin Score (mRSS) was lower in the ANA-negative group (2.4 points lower, p = 0.05). Furthermore, they experienced more malabsorption (p = 0.05). There was no difference in the frequency of pulmonary fibrosis or scleroderma renal crisis. All-cause mortality was not different between the 2 groups (p = 0.28). CONCLUSIONS: In conclusion, the results of this study suggest that SSc patients who are ANA negative constitute a distinct subset of SSc with less vasculopathy (less PAH, digital ulcers, and fewer telangiectasias), a greater proportion of males, and possibly, more frequent lower gastrointestinal involvement.
Authors: E C LeRoy; C Black; R Fleischmajer; S Jablonska; T Krieg; T A Medsger; N Rowell; F Wollheim Journal: J Rheumatol Date: 1988-02 Impact factor: 4.666
Authors: Vivien M Hsu; Abel E Moreyra; Alan C Wilson; Meir Shinnar; Daniel M Shindler; Julianne E Wilson; Ami Desai; James R Seibold Journal: J Rheumatol Date: 2008-01-15 Impact factor: 4.666
Authors: Y Hamaguchi; M Hasegawa; M Fujimoto; T Matsushita; K Komura; K Kaji; M Kondo; C Nishijima; I Hayakawa; F Ogawa; M Kuwana; K Takehara; S Sato Journal: Br J Dermatol Date: 2008-01-17 Impact factor: 9.302
Authors: Julie Morisset; Eric Vittinghoff; Brett M Elicker; Xiaowen Hu; Stephanie Le; Jay H Ryu; Kirk D Jones; Anna Haemel; Jeffrey A Golden; Francesco Boin; Brett Ley; Paul J Wolters; Talmadge E King; Harold R Collard; Joyce S Lee Journal: Chest Date: 2017-06-16 Impact factor: 9.410
Authors: Raquel Freitas; Patrícia Martins; Eduardo Dourado; Tânia Santiago; Francisca Guimarães; Bruno Miguel Fernandes; Salomé Garcia; Beatriz Samões; Ana Sofia Pinto; Nuno Gonçalves; Maria Helena Lourenco; Emanuel Costa; Margarida Rocha; Maura Couto; Ana Catarina Duarte; Filipe Araújo; Inês Cordeiro; Fátima Godinho; Catarina Resende; Maria João Salvador; Ana Cordeiro; Maria José Santos Journal: Clin Rheumatol Date: 2021-11-20 Impact factor: 2.980
Authors: Karin A L Mueller; Iris I Mueller; David Eppler; Christine S Zuern; Peter Seizer; Ulrich Kramer; Ina Koetter; Martin Roecken; Reinhard Kandolf; Meinrad Gawaz; Tobias Geisler; Joerg C Henes; Karin Klingel Journal: PLoS One Date: 2015-05-12 Impact factor: 3.240